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IntheUnitedStates,renalcellcarcinoma(RCC)accountsforapproximately3%ofadultmalignanciesand90–95%ofallneoplasms
arisingfromthekidney.AccordingtotheNationalCancerInstitute,58240newcasesand13040deathsfromrenalcancerwilloccur
in 2010. RCC usually occurs in older adults between the ages of 50 and 70 and is rare in young adults and children. We describe
a case of a TFE3 translocation-associated RCC in a 19-year-old patient presenting as avascular necrosis of the femur. Due to the
rarity of this malignancy, we present this case including a review of the existing literature relative to diagnosis and treatment.
1.Introduction
In the United States, renal cell carcinoma (RCC) accounts
for approximately 3% of adult malignancies and 90–95% of
all neoplasms arising from the kidney. The incidence varies
depending on racial and ethnic characteristic [1]. According
to the National Cancer Institute an estimated 58240 new
cases and 13, 040 deaths from renal cancer will occur in
2010. RCC usually occurs in older adults between the ages
of 50 and 70 and is rare in young adults and children
[2]. Predisposing conditions, known to increase the risk of
RCC, include cigarette smoking, obesity, hypertension, and
diabetes mellitus. Several studies suggest also an association
between development of RCC and other factors, such as
physical activity, alcohol consumption, acrylamide intake,
occupational and environmental exposure to trichloroethy-
lene and heavy metals such as cadmium, lead, and arsenic,
and parity in women [1]. Genetic susceptibility was also
shown to play a major role in inherited RCC, for example,
Hippel-Lindau (VHL) disease [3], shorter telomere length
in peripheral blood lymphocyte DNA [4]. Additionally,
multiple other genetic variations were found to be associated
with RCC risk; however only limited evidence is available
[4–12]. Nephroblastoma are Wilm’s tumor are the most
common types of kidney cancer in children and younger
adults.Itcomprisesapproximately1.2% ofallkidney cancers
[1]. The clear cell subtype of RCC is most common, followed
byRCCnototherwisespeciﬁed,papillary,andchromophobe
subtypes [1]. The diﬀerent histological subtypes have well-
documented clinical and genetic characteristics [13, 14]. The
ﬁrst detailed morphological characterization of these tumors
waspublishedbyArganietal.in2001[15].In2004,theXp11
translocation RCC was introduced as a genetically distinct
entity into the World Health Organization classiﬁcation of
renal neoplasms [16, 17]. This subtype occurs especially in
the pediatric age group, where it accounts for at least one-
third of RCCs and for 15% of RCCs in patients <45 years
of age [18]. Most of these papillary RCCs exhibit certain
cytogeneticabnormalities,includingt(X;1)(p11.2;q21),t(X;
1)(p11.2;p34),(X;17)(p11.2;q25.3),andinv(X)(p11.2;q12)
[19]. These translocations result in gene fusions involving
the TFE3 transcription factor gene which maps to this
locus [20–23]. Even though the functions of TFE3 are2 Case Reports in Medicine
Figure 1: X-ray of the pelvis (anterior-posterior) showing patho-
logical fracture of the left femur neck (arrow).
not completely deﬁned yet, it has been described as being
important for stimulation of the plasminogen activator
inhibitor 1 (PAI-1) gene promoter by TGF-b in conjunction
with Smad3 and Smad4 [24] and for osteoclast development
[25]. The diagnosis of an Xp11 translocation can be made by
immunohistochemistry with antibodies against TFE3. TFE3
is not detected by this method in normal tissue.
Information about the natural history is sparse; however
the evidence is mounting that patients with metastatic
Xp11 translocation RCC have aggressive disease that usually
presents at an advanced stage [18, 26–32]. Herein, we
describe a case of a TFE3 translocation-associated RCC in a
19-year-old patient presenting initially as avascular necrosis
of the femur. Due to the rarity of this malignancy, we
present this case including a review of the existing literature
relative to diagnosis and treatment. We will also characterize
the tumor by immunohistochemistry and its response to
diﬀerent treatment regimens. By documenting the response
to various treatments this paper should help to ﬁnd optimal
treatment regimens for this particular clinical situation.
2.CaseReport
2.1. Initial Presentation. Our patient was a 19-year-old male
who had approximately one year of mild-to-moderate low
back pain, for which he was being treated by a chiropractor.
After development of left hip pain, X-ray examination
showed osteopenia of the left femoral head and neck.
The diagnosis of Perthes’ disease was made and treated
accordingly. The patient was placed on nonweight-bearing
status of the left hip after a fall. 3 months later he suﬀered
a pathological fracture to the left femur neck (Figure 1). A
CT scan of the abdomen and pelvis revealed a large left-
sided renal mass measuring 11.5 × 10.7cm, consistent with
a renal neoplasm. The patient was referred to our institution
for management.
2.2. Hospital Course. The patient had no relevant past medi-
cal and surgical history. Family history was noncontributory,
speciﬁcally no history of malignant diseases. Social history
was also unremarkable, particularly no history of tobacco,
alcohol, or drug use or exposure to toxins or carcinogens.
Physicalexaminationrevealedanormallydeveloped19-year-
old male. Tenderness of the left hip region on deep palpation
was encountered, as well as tenderness to palpation in the
lowerback.Apalpableﬁrmmasswasencounteredintheleft-
sided abdomen.
Admission laboratory studies were WBC 7.7kU/L, HGB
13.1g/dL, RBC 4.01M/UL, platelets 241kU/L, and hemat-
ocrit 37.7%. His blood urea nitrogen was 11mg/dL, creati-
nine0.7mg/dL.Urinalysiswaspositivefornitrite,blood,and
leucocytes. Liver function test was ALT 10intlunits/L, AST
54intlunits/L, LD 327units/L, total bilirubin 0.4mg/dL,
total protein 6.9g/dL, albumin 3.9g/dL. Alkaline phos-
phatase was 79intlunits/L.
Initial diﬀerential diagnosis included possible metastatic
renal cell cancer, Wilm’s tumor, or lymphoma. CT scan of
the abdomen and pelvis showed a large heterogeneously
enhancing exophytic left renal mass measuring 11.6 ×
10.7cm, inﬁltrating the renal pelvis and lower pole calyceal
system. The mass had multiple small calciﬁcations. The mass
extended to the left lateral and posterior abdominal wall
without evidence of inﬁltration or solid organ involvement
and without signiﬁcant lymphadenopathy. The ﬁndings
c o u l db ec o n ﬁ r m e db yM R I( Figure 2). CT scan examination
of the head, lung, and mediastinum was normal.
There was an osteolytic lesion involving the L4 vertebral
body anteriorly with prevertebral soft tissue component and
osteolytic lesions involving the left proximal femur and left
acetabulum.
The bone scan demonstrated a very mild salt-and-
pepper appearance to the skull, sternum, and posterior ribs.
The axial skeleton showed increased radionuclide activity
throughout the entire diaphysis of the left femur as well
as the lower lumbar spine and midsternum. There was
also increased radionuclide activity at the posterior left
hemipelvis, suggestive of metastatic disease to the axial
skeleton and the lower appendicular skeleton (Figure 3).
Percutaneous biopsies of the tumor showed a mixture
of spindle cell (predominant) and epithelioid cells with
abundant amphophilic, clear, and focally granular pink
cytoplasm. Epithelioid cells often line spaces, spindle cells
form fascicles. Necrosis is not present (Figure 4). The
selective immunophenotype was inconclusive. Immunoper-
oxidase stains: are as following. Positive: MS Actin (focally
positive, 0-1+); Myo-D1 (Clarient); EMA (rare); CD10
(only RARE positive cells). Negative: Vimentin (back-
ground vessels positive, no clearly positive tumor cells),
CKAE1/AE3, Desmin (some vessels positive); Inhibin, RCC,
Melan A(MART1)(Clarient). A variety of tumors were
in the diﬀerential diagnosis included, including alveolar
soft part sarcoma, alveolar rhabdomyosarcoma, chromo-
phobe carcinoma, translocation renal cell carcinoma, and
atypical angiomyolipoma, but the mixed pattern of his-
tology required further immunohistochemistry for ﬁnal
diagnosis.
The patient was discussed at a multidisciplinary tumor
board meeting, where it was agreed that a radical tumor
nephrectomy with the intention of tumor debulking wasCase Reports in Medicine 3
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Figure 2: MRI and CT scan (inset (a) without IV contrast and (b) with IV contrast) of the abdomen and pelvis showing a large het-
erogeneously enhancing (inset (b)) exophytic left renal mass measuring 11.6 × 10.7cm with multiple small calciﬁcations (arrow inset (a)).
indicated. The patient was also scheduled for curettage
and bone grafting of the metastatic femur lesion and
left periacetabular region and calcar-replacing left total
hip arthroplasty. On hospital days 5 and 10 the patient
underwentleftradicalnephrectomyviachevronincisionand
orthopedic surgery.
Intraoperatively the retroperitoneum demonstrated
extensive number of dilated blood vessels and dramatically
dilated lymphatics, measuring up to 6–8mm in diameter
coursing over the surface of the kidney, Gerota’s fascia, and
the mesentery to the left colon. These dilated lymphatics
extended over the aorta and up to the renal hilum. Both
surgeries went uneventful.
Pathological examination showed an intact kidney with-
out perinephric fat measuring 18 × 12 × 7cm and weight of
920g. Approximately 90% of the kidney had been replaced
by the tumor, except for a rim of upper pole that measured
6 × 3 × 2cm. The tumor was unifocal measuring 12cm
greatest dimension. The tumor was a solid, tan-pink mass
with hemorrhage and necrosis, limited to the kidney, well
circumscribed,andgrosslyconﬁnedbytherenalcapsule.The
uninvolved renal parenchyma was unremarkable (Figure 5).4 Case Reports in Medicine
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Figure 3: Whole body bone scan performed after left hip
replacement showing mild salt-and-pepper appearance to the skull,
sternum, and posterior ribs. The axial skeleton and the posterior
left hemipelvis showed increased radionuclide activity suggestive of
metastatic disease to these regions.
Microscopically, the renal tumor was composed of
relatively large and uniform epithelioid cells with clear to
vacuolated to eosinophilic cytoplasms. The tumor showed a
nesting ortrabeculargrowthpatterns.Thenucleishowinter-
mediate grade features but overall have a bland appearance.
Mitotic activity was sparse.
The immunostainings were negative for melan-A and
the melanoma cocktail. This tumor was also nonreactive
for EMA, CD10, pancytokeratin, CK7, CD68, CD34 and
E-cadherin Mart 1, HMB45, and CKAE1/AE3. Vimentin
highlighted an occasional tumor cell. PAS with and without
diastase and colloidal iron stains was equivocal (Figure 6).
After reviewing the immunostains and given the fact that
the tumor is clearly metastatic to the young man’s femur, we
includedalveolarsoftpartsarcomainthediﬀerentialdiagno-
sis. We performed further immnostains which conﬁrm that
the tumor is negative for pancytokeratin and melan-A. This
tumor displayed focal positivity for smooth muscle actin and
vimentin. Finally, nuclear positivity for TFE-3 was present
(Figure 6). TFE-3 expression would imply that there is an
Xp11.2 translocation. These ﬁndings were consistent with
classiﬁcationofthetumorasaTFE3translocation-associated
renal cell carcinoma. This is supported by the strong nuclear
positivity for TFE3 in the absence of signiﬁcant background
staining in our hands, the negativity for vimentin (which
wouldbehighlyunusualforepithelioidangiomyolipoma),as
well as the negativity in everyone’s hands for all melanocytic
markers. The biopsy from the left femur demonstrates a
similar histology. The tumor was staged accordingly as
Xp11.2 translocation renal cell carcinoma with smooth
muscle actin positivity, pT2b, pNx, pM1(bone).
Based on the histopathological characteristics of the
tumor (clear cell carcinoma with sarcomatoid features)
(a)
(b)
Figure 4: H&E stainings ((a) 200x and (b) 400x magniﬁcation)
of the tumor showing a mixture of spindle cell (predominant)
and epithelioid cells with abundant amphophilic, clear, and focally
granular pink cytoplasm. Epithelioid cells often line spaces, spindle
cells form fascicles.
and its metastatic spread, chemotherapy according to
the AREN0321Treatment Regimen for High Risk Renal
Tumors was initiated. The treatment regimen of a 4-
week cycle included Cyclophosphamide: IV over 1 hour
1200mg/m2/day, week 1; Doxorubicin: IV over 120 minutes
on Day 1 dose 45mg/m2/day; Vincristine: IV Day 1wks 1–
3 = 1.5mg/m2/day; Carboplatin: IV over 1 hour on Day 1
of week 4; cyclophosphamide: IV over 15–30 minutes on
Days 1–4 of week 4 dose 440mg/m2/day. Additionally, the
patient received palliative radiation therapy with a total dose
of3500cGyin15fractionsusingthe3Dconformaltechnique
with the 15MV unit to the pelvis/left hip and to the C-
spine and left shoulder with a total dose of 3150cGy given
in 8 fractions also using the 3D conformal technique with
the 6MV unit. The patient developed disease progression
under this chemotherapy/radiation regimen and was started
on Vincristine: IV Day 1 of weeks 1-2 dose 1.5mg/m2/dose
and Irinotecan: IV 20mg/m2/daily X 5 according to the
COG protocol for unresponsive renal masses. No signiﬁcant
response was noted. It was decided to start the patient
on a combination regimen consisting of Sorafenib plus
Irinotecan. This combination resulted in stable disease forCase Reports in Medicine 5
Figure 5: Radical nephrectomy specimen demonstrating an intact
kidney mass without perinephric fat measuring 18 × 12 × 7cmand
weight of 920g. The tumor appears as solid, tan-pink, and well-
circumscribed mass grossly conﬁned by the renal capsule. Of note
is the extensive number of dilated blood vessels and lymphatics.
Figure 6: Immunostaining demonstrating strong nuclear positivity
for TFE3 protein with only minimal background staining.
approximately 8 weeks. However, this combination caused
signiﬁcant diarrhea, and Sorafenib was stopped. Finally,
the patient was treated with a combination of Irinotecan,
Temsirolimus, and Bevacizumab. Despite a negative PET
scan the patient developed clinically progressive disease
under treatment and died secondary to multisystem failure.
3. Discussion
Solid tumors of the kidney are the third most common
malignancies in children and young adults. While Wilms
tumor being the most frequent and well-studied entity, RCC
is rare and is responsible for only 0.3% of all malignancies
and up to 6.3% of all malignant renal tumors in this age
group [33]. Because of this fact little is known regarding
possible causes of RCC in this age group and treatment.
A few case series reports have been published in the
literature [33–35]. Indolﬁ et al. published in 2003 one of
the largest clinicopathological studies involving 41 patients
with a median age of 10 years [33]. In this study, clear cell
carcinoma had with 59% of the cases a similar incidence rate
compared to adult series. In addition, the overall outcome
of RCC in pediatric patients is comparable to the outcome
in adults. Several studies deﬁned the stage of the disease
at presentation as major factor inﬂuencing the prognosis.
Tumors localized to the kidney have a better prognosis than
tumors with regional lymph node involvement or distant
metastatic disease [33, 34]. On the contrary, Geller and
Dome found that lymph node involvement is not an adverse
prognostic factor for pediatric RCCs in contrast to the
presenceofdistantmetastases[35].Asdescribedfortheadult
patient population an obvious association of von Hippel-
Lindau (VHL) disease or tuberous sclerosis complex with
RCCexists[36,37].IncaseoftheVHL,agermline mutation
on chromosome 3p is linked to the development of RCC
[38].ItisnoteworthythatRCCsinchildrenandyoungadults
often have a pseudopapillary architecture. Over the last 20
years a new cytogenetic subtype involving the chromosome
band Xp11.2 in pediatric and adult RCC patients has
been described [20–23]. The t(X; 1)(p11; q21) is the most
frequent translocation resulting in the PRCC-TFE3 gene
fusion [20]. Although TFE3 RCC represents only a relatively
small portion of renal tumors in childhood and young
adults, these tumors seem to have diﬀerent characteristics in
terms of histologic patterns, biologic behavior, and possible
response to treatment. Malouf et al. analyzed the beneﬁt
of targeted therapy (vascular endothelial growth factor
receptor- (VEGFR-) targeted agents and/or mammalian
target of rapamycin (mTOR) inhibitors) in patients with
Xp11 translocation/TFE3 fusion gene metastatic RCC [32].
In their retrospective study, patients with Xp11 translo-
cation mRCC displayed aggressive disease with a median
progression-freesurvival(PFS)of2monthswhenreceivinga
cytokine-based regimen and an 11% response rate. VEGFR-
targeted and/or mTOR inhibitor treatment demonstrated an
objective response rate of 33% of the patients. Interestingly,
patients treated with sunitinib had an 8.2-month PFS, which
is similar to clear cell RCC. The group concluded that
response to targeted therapy does not depend necessarily
on RCC subtype [32]. As seen in our patient chemotherapy
is not eﬀective. Sunitinib is achieved in combination with
irinotecan stable disease. This ﬁnding is in concordance with
the results form Malouf et al., which described a better PFS
in patients on ﬁrst-line sunitinib than in those receiving
cytokines. Sunitinib seems to be eﬀective in patients with
TFE3 RCC as 7 of 14 of their treated patients achieved a
partial (n = 6) or complete (n = 1) response [32].
In summary, TFE3 RCC is a rare malignancy where the
genetic background may not only contribute to tumorigen-
esis, but also determine the response to chemotherapy and6 Case Reports in Medicine
targeted therapy. Therefore it is necessary to diagnose this
tumor entity accurately. Histomorphological and immuno-
histochemical features were previously described by Argani
et al., which may help pathologists in distinguishing these
neoplasms from their mimics [20, 39]. Because of the small
number of TFE3 gene fusion-related renal tumors described
in the literature, the exact biologic behavior and impact
of current treatment modalities remain to be uncertain.
Increased awareness among urologists, pathologists, and
oncologist is necessary in order to help in identifying
more cases of this phenotype in the future. Prospective
randomized studies on novel targeted agents are needed
to identify the optimal treatment strategy for this speciﬁc
patient population. In addition, a better characterization of
the genetics of these translocations will help to develop more
speciﬁc drugs.
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